InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
1
T+90 hit rate
22%
T+90 mean return
-9.4%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by CLARK IAN T, Director. Officer active across 6 companies, notably AGIOS PHARMACEUTICALS, INC.. Aggregated, 17 reports have been published. Split: 0 buy · 1 sell. Total volume traded: €632k. History available since 28 May 2021. The latest transaction was disclosed on 2 June 2026 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations17 total
5,092 sharesCommon StockSEC:0001336504-26-000004:0
7,490 shares0Common StockSEC:0001628280-26-040909:0
5,093 shares0Common StockSEC:0001193125-26-248435:0
6,876 shares@ US$106.90060.0050% mcap97.0% of flowCommon StockSEC:0001336504-26-000002:0
7,000 shares0Common StockSEC:0001048477-25-000095:0
1,076 shares@ US$4.180.6% of flowCommon StockSEC:0001576280-24-000279:0
25,852 shares0Class A Common StockSEC:0001809519-24-000141:0
6,776 shares0Common StockSEC:0001576280-24-000132:0
6,703 shares0COMMON STOCKSEC:0001576280-23-000091:0
2,198 shares0COMMON STOCKSEC:0001576280-22-000034:0
1,585 shares0Common stockSEC:0001439222-22-000052:0
1,076 shares@ US$4.180.6% of flowCOMMON STOCKSEC:0001576280-21-000088
1,076 shares@ US$4.180.0000% mcap25.1% of flowCOMMON STOCKSEC:0001576280-21-000088:0
1,076 shares@ US$4.180.0000% mcap24.9% of flowCOMMON STOCKSEC:0001576280-21-000072:0
1,076 shares@ US$4.180.6% of flowCOMMON STOCKSEC:0001576280-21-000072
1,686 shares0Common stockSEC:0001439222-21-000055
1,686 shares0Common stockSEC:0001439222-21-000055:0
17 of 17 declarations
About CLARK IAN T
Ian T. Clark is a Board Member at Agios Pharmaceuticals, Inc. and Guardant Health, Inc. He contributes to the governance of these companies by participating in strategic decision-making and oversight of operations. His expertise is valuable for their development.
